Literature DB >> 10064244

Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community.

H M Malaty1, D Y Graham, W A Wattigney, S R Srinivasan, M Osato, G S Berenson.   

Abstract

We assessed the pattern of acquisition and loss of Helicobacter pylori infection in a cohort of 212 children from a biracial community with a homogeneous socioeconomic class. The children were followed over 12 years (1973-1974 to 1985-1986) from childhood to young adulthood. H. pylori status was assessed by the presence of serum IgG antibodies to H. pylori. At ages 7-9, 19% of children had H. pylori infection (40% of blacks vs. 11% of whites; P = .0001); 12 years later, 33% were seropositive. The higher prevalence among blacks remained (P = .0001). During follow-up, 22% of children became infected; the rate of acquisition was fourfold greater among blacks than among whites (P = .001). Over the 12-year period, infection was lost in 50% of whites compared with 4% of blacks who either remained infected or became reinfected. H. pylori infection in childhood is affected by both acquisition and loss of infection in different ethnic groups. This observation is critical for understanding the epidemiology and transmission of H. pylori infection.

Entities:  

Mesh:

Year:  1999        PMID: 10064244     DOI: 10.1086/515105

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

Review 1.  New approaches to Helicobacter pylori infection in children.

Authors:  B D Gold
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 2.  Helicobacter pylori infection and eradication in paediatric patients.

Authors:  H M Malaty
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

3.  Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors.

Authors:  Jed W Fahey; Xavier Haristoy; Patrick M Dolan; Thomas W Kensler; Isabelle Scholtus; Katherine K Stephenson; Paul Talalay; Alain Lozniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Race, African ancestry, and Helicobacter pylori infection in a low-income United States population.

Authors:  Meira Epplein; Lisa B Signorello; Wei Zheng; Richard M Peek; Angelika Michel; Scott M Williams; Michael Pawlita; Pelayo Correa; Qiuyin Cai; William J Blot
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-02-25       Impact factor: 4.254

5.  Characteristics of Helicobacter pylori infection in Jamaican adults with gastrointestinal symptoms.

Authors:  M Hisada; M G Lee; B Hanchard; M Owens; Q Song; L J van Doorn; A F Cutler; B D Gold
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

6.  Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Eiko Kanda; Masahiko Sasajima; Kazumasa Miki
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

7.  Helicobacter pylori-specific immune responses of children: implications for future vaccination strategy.

Authors:  Günter Bode; Isolde Piechotowski; Dietrich Rothenbacher; Hermann Brenner
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Natural acquisition of Helicobacter pylori infection in newborn rhesus macaques.

Authors:  Jay V Solnick; Kikuko Chang; Don R Canfield; Julie Parsonnet
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

9.  Helicobacter pylori: a poor man's gut pathogen?

Authors:  Mohammed Mahdy Khalifa; Radwa Raed Sharaf; Ramy Karam Aziz
Journal:  Gut Pathog       Date:  2010-03-31       Impact factor: 4.181

10.  Antibiotics taken for other illnesses and spontaneous clearance of Helicobacter pylori infection in children.

Authors:  Cheryl S Broussard; Karen J Goodman; Carl V Phillips; Mary Ann Smith; Lori A Fischbach; R Sue Day; Corinne C Aragaki
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-08       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.